# Navigating Regulated Promotional Claims
A pharma marketing team once launched a slick campaign for a cardiac drug. The problem: a company-sponsored speaker mentioned a use the FDA had never approved. Months later, the FDA's Office of Prescription Drug Promotion (OPDP) sent a warning letter. The company had to run corrective advertising, pull materials, and absorb reputational damage. One sentence, spoken off-script, triggered it all.
Welcome to marketing in a world where a single claim can become a federal enforcement action. This is not a reason to be timid. It is a reason to be precise.
In most industries, you can say almost anything short of outright fraud. In biotech and medtech, promotion is regulated because the product can hurt or kill people if used wrong.
Two terms to define upfront:
On-label means promoting a product only for the uses, doses, and populations the FDA approved, as written in the official prescribing information (the "label," a detailed document, not the sticker on a bottle).
Off-label promotion means marketing a product for an unapproved use. Doctors are legally allowed to prescribe off-label. Companies are largely not allowed to promote off-label. That asymmetry trips up a lot of marketers.
The FDA regulates drug and biologic promotion mainly through OPDP. Medical devices fall under a different center but similar principles apply.
FDA warning letters are public. They are one of the best free training resources in this field. You can browse them on the
Most promotional letters cite one or more of these violations:
Omitting or minimizing risk. A banner ad shouts efficacy but buries side effects in tiny text. Regulators call this a lack of "fair balance." Benefit and risk information must be presented with comparable prominence.
Overstating efficacy. Claiming a drug "cures" a condition it only manages, or implying superiority to a competitor without head-to-head clinical data to back it.
Broadening the indication. The drug is approved for severe cases; the ad implies it works for mild ones too.
Off-label claims. The most serious category. Promoting an unapproved use, dose, or patient group.
Read three or four letters and you will start seeing the same patterns. Marketers cause them by chasing persuasion without a regulatory guardrail.
🎬 [VIDEO: "FDA Regulation of Prescription Drug Promotion" — youtube.com — an accessible overview of what OPDP reviews and how promotional rules work]
The Physician Payments Sunshine Act requires manufacturers to publicly report payments and transfers of value to physicians and teaching hospitals. That includes meals, travel, speaking fees, and consulting. The data lives in the CMS Open Payments database, searchable by anyone.
Why does a marketer care? Because relationships are a marketing channel, and this one is fully transparent.
A common violation pattern: a company hosts "educational" dinners that are really thinly veiled sales events, gives physicians lavish meals, and either misreports or fails to report the spend. When the numbers do not match reality, it signals to regulators that the underlying activity may have been an improper inducement.
The lesson: every speaker program, advisory board, and dinner is both a marketing tactic and a reportable transaction. Design them to survive public scrutiny. If a journalist pulled your Open Payments record tomorrow, would the story write itself as "education" or as "buying prescriptions"?
Compliance is not the enemy of persuasion. Constraints force sharper creative. Here is how strong teams build campaigns that hold up.
Before any creative concept, pull the approved indication and the clinical data. Your claims can only go as far as the evidence and the label allow. If the trial measured symptom reduction at 12 weeks, you cannot imply lifelong benefit.
Substantiation is the rule: every claim needs a citable source, usually the label or a peer-reviewed publication.
Promotion to healthcare professionals (HCPs) can use clinical, technical language. Direct-to-consumer (DTC) promotion, which is legal in the US but rare globally, faces stricter readability and risk-disclosure requirements. The famous rapid-fire side effect list in TV ads exists because of fair balance rules.
A defensible promotional claim usually pairs:
1. The benefit statement (on-label, substantiated).
2. The supporting evidence (citation).
3. The balancing risk information (prominent, not buried).
Example structure (illustrative, not a real product): "In a 12-week trial, Drug X reduced [approved endpoint] versus placebo.¹ The most common side effects were [list]. See full prescribing information."
Notice what is missing: no "best in class," no unproven comparison, no hint of an unapproved use.
Nothing goes out the door without MLR review: Medical, Legal, and Regulatory review. This is the internal committee that vets every promotional piece before use.
MLR is where marketers either build trust or become the bottleneck's cause. Tips that make it faster:
Annotate everything. Attach a reference for every claim in the piece, mapped to the exact sentence. Reviewers should never hunt for your source.
Submit clean, near-final work. MLR is not a brainstorm. Bring polished concepts with claims already substantiated.
Learn the precedent. If a claim was approved last quarter, reuse the approved language. Reinventing wording restarts the debate.
Use a claims library. Mature teams maintain a database of pre-approved claims with linked references and expiration dates (references age out). Marketers assemble campaigns from approved building blocks.
Many companies now run MLR through digital asset management platforms that track versions, references, and approvals in an audit trail. That trail matters: if the FDA ever asks how a claim was vetted, you can show your work.
Vérification des acquis
1. A physician prescribes a drug for a condition the FDA has not approved it to treat, while the manufacturer's sales rep separately promotes the drug for that same unapproved use. Which statement best describes the legal situation?
2. Why is promotion of biotech and medtech products regulated more strictly than in most other industries?
3. An ad emphasizes a drug's benefits prominently while relegating its side effects to small, hard-to-read text. What regulatory concept does this most directly violate?
4. Select ALL correct answers about what 'on-label' promotion requires.
Sélectionnez toutes les réponses correctes.
5. Select ALL correct answers about FDA warning letters and their value to marketers.
Sélectionnez toutes les réponses correctes.
Warning letters often trace back to the field, not the ad agency. A sales representative goes off-script in a doctor's office, and there is no MLR to catch it in real time.
Reps should know the approved indication cold and recognize when a conversation drifts off-label. The safe move when a physician asks about an unapproved use: route the question to Medical Affairs, a separate scientific function that can respond to unsolicited requests through compliant channels. Sales does not answer off-label questions; Medical does.
That firewall between commercial (sales, marketing) and medical functions is deliberate. It keeps scientific exchange from becoming disguised promotion.
Reps present only MLR-approved visual aids and leave-behinds. No self-made slides, no marked-up printouts, no "here is an interesting article" that promotes off-label. The abstract a rep hands over is itself a promotional act.
Companies build compliance into incentive plans and monitoring. Some record or shadow sales calls for training. The goal is a culture where staying compliant is the path of least resistance, not a constant fight against quota pressure.
The best sector marketers reframe the constraint. Regulators effectively force you to sell on evidence. In a field where physicians are skeptical and outcomes matter, evidence is the most persuasive asset you have.
A campaign built on real clinical data, honest about risk, and citable to its source is not just compliant. It is more credible to a physician than any superlative. Trust is the currency, and compliance is how you earn it at scale.